Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, has been named “Life Science Company of the Year” at the 4th Cambridge Independent Science and Technology Awards. The Award recognises the potential of Evonetix’s novel gene synthesis technology, as well as the Company’s recent achievements. These include the close of a $30M (£24M) Series B investment round, commercial partnerships with global industry leaders such as ADI and imec, and continued expansion. Evonetix aims to add staff across all areas of its technology including marketing and business development as it gears up for product launch.
Evonetix’s novel platform has the potential to facilitate the rapidly growing field of synthetic biology. It will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used which will have a huge impact on enabling the growing multi-billion dollar synthetic biology industry. The technology is based on a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of up to 10,000 miniaturised reaction sites.
The Cambridge Independent Science and Technology Awards recognise outstanding life science and biotechnology companies in Cambridge. The ceremony took place virtually in a bespoke interactive environment, and was attended by leaders of businesses, organisations and research institutes across the Cambridge region on April 15, 2021.
Our approach to synthesising long DNA at unprecedented accuracy and scale will have a great impact on the field of synthetic biology. This prestigious award recognises all that that the team at Evonetix has achieved in the last year, despite the challenging conditions.Dr Tim Brears, Evonetix CEO